Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • CDSCO issues PUBLIC...

    CDSCO issues PUBLIC NOTICE asking for feedback on online portal SUGAM

    Farhat NasimWritten by Farhat Nasim Published On 2018-12-09T09:25:58+05:30  |  Updated On 9 Dec 2018 9:25 AM IST
    CDSCO issues PUBLIC NOTICE asking for feedback on online portal SUGAM

    All stakeholders of SUGAM are requested to provide their valuable feedback as per enclosed format with suggestions about the short-term, medium-term and long-term measures to be taken to improve the system. The feedback should be forwarded to feedback@cdsco.nic.in within 2 weeks of this notice in scanned pdf format as well as excel document format.


    New Delhi: The Central Drugs Standard Control Organisation(CDSCO) has sought feedback from users, including manufacturers, importers, research and development institutions, and clinical research organisations about its web portal 'SUGAM' to further improve it.


    Through a public notice, CDSCO announced to keep in line with Govt of India's vision to promote Digital India and Ease of Doing Business, CDSCO thrives to strengthen this online SUGAM portal to enhance public confidence in the quality, safety and efficacy of drugs marketed in India as well as to satisfy the applicants.


    CDSCO further adds, as "SUGAM" online system (www.cdscoonline.gov.in) has completed 2 years and all stakeholders well converse, it would be appropriate to obtain feedback from the stakeholder to improve the system. A detailed feedback form is enclosed as Annex-I.


    All stakeholders are requested to provide their valuable feedback as per the format with suggestions about the short-term, medium-term and long-term measures to be taken to improve the system. The feedback should be forwarded to feedback@cdsco.nic.in within 2 weeks of this notice in scanned pdf format as well as excel document format.


    SUGAM is an e-Governance system to discharge various functions performed by the CDSCO under the Drugs and Cosmetics Act, 1940. Through the web portal, people can apply for NOCs, licenses, registration certificates, permissions and approvals. It provides an online interface for applicants to track their applications, respond to queries and download the permissions issued by CDSCO.


    It also enables CDSCO officials to process the applications online.


    Also Read: Application for Bulk Vaccine to be filed mandatorily through SUGAM: CDSCO

    CDSCOCentral Drugs Standard Control Organisationdevice newsDrugs and Cosmetics Actfeedback@cdsco.nic.inmedical newsNOCspharma newsSugamsugam feedbackSUGAM portalwww.cdscoonline.gov.in
    Source : With input

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok